Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Erythromycin Propionate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 0.95 |
| ▸ | SLCO1B3 | Q9NPD5 | 3/20 | 0.95 |
| ▸ | SLCO1B1 | Q9Y6L6 | 3/20 | 0.95 |
| ▸ | USP2 | O75604 | 3/20 | 0.95 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.95 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.95 |
| ▸ | MEN1 | O00255 | 1/20 | 0.95 |
| ▸ | TP53 | P04637 | 1/20 | 0.95 |
| ▸ | MAPT | P10636 | 1/20 | 0.95 |
| ▸ | HPGD | P15428 | 1/20 | 0.95 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.95 |
| ▸ | RECQL | P46063 | 1/20 | 0.95 |
| ▸ | BLM | P54132 | 1/20 | 0.95 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.95 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.95 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.82 |
| ▸ | PGR | P06401 | 1/20 | 0.80 |
| ▸ | HTR1A | P08908 | 1/20 | 0.80 |
| ▸ | DRD1 | P21728 | 1/20 | 0.80 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Erythromycin Propionate SCHEMBL343123 | 0.98 | CYP3A4 (0.94) | CYP3A4SLCO1B3SLCO1B1USP2ABCB11 | |
| Erythromycin Propionate SCHEMBL3331 | 0.97 | CYP3A4 (1.00) | CYP3A4SLCO1B3SLCO1B1USP2ABCB11 | |
| Erythromycin Propionate SCHEMBL29400629 | 0.97 | CYP3A4 (1.00) | CYP3A4SLCO1B3SLCO1B1USP2ABCB11 | |
| Erythromycin Propionate SCHEMBL25223334 | 0.97 | CYP3A4 (1.00) | CYP3A4SLCO1B3SLCO1B1USP2ABCB11 | |
| Erythromycin Ethylsuccinate SCHEMBL28122248 | 0.95 | CYP3A4 (0.92) | CYP3A4SLCO1B3SLCO1B1USP2ABCB11 | |
| Erythromycin SCHEMBL3473986 | 0.92 | ABCB11 (0.95) | CYP3A4SLCO1B3SLCO1B1USP2ABCB11 | |
| Erythromycin SCHEMBL11319266 | 0.90 | ABCB11 (1.00) | CYP3A4SLCO1B3SLCO1B1USP2ABCB11 | |
| Erythromycin SCHEMBL11319270 | 0.90 | ABCB11 (1.00) | CYP3A4SLCO1B3SLCO1B1USP2ABCB11 | |
| Erythromycin SCHEMBL7597003 | 0.90 | ABCB11 (1.00) | CYP3A4SLCO1B3SLCO1B1USP2ABCB11 | |
| Erythromycin SCHEMBL7597008 | 0.90 | ABCB11 (1.00) | CYP3A4SLCO1B3SLCO1B1USP2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| WO-2021055690-A1 | PEPTIDE-CONJUGATED PRODRUGS | BRANDEIS UNIVERSITY (US) | 2021-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | CYP3A4 2117/4885SLCO1B3 1776/4885SLCO1B1 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.